The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
32 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,697,710 in first-year total cost, median $239,225.
Most frequent study sections
- Special Emphasis Panel[ZDA1 SKM-D (06)]12
- Special Emphasis Panel[ZDA1 TXT-V (01)]10
- Special Emphasis Panel[ZDA1 TXT-V (05)]10
Most frequent institutions
- UNIVERSITY OF TEXAS MED BR GALVESTON4
- RESEARCH TRIANGLE INSTITUTE3
- JOHNS HOPKINS UNIVERSITY2
- MCLEAN HOSPITAL2
- OREGON HEALTH & SCIENCE UNIVERSITY2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Targeting Leptin Pathway to Treat Opioid-Induced Respiratory Depression1U18DA052301-01 | POLOTSKY, VSEVOLOD Y | JOHNS HOPKINS UNIVERSITY, MD | $259,438 | ZDA1 |
| 2021 | Characterization GPR83 and identification of small molecule ligands targeting this receptor for the treatment of substance use disorders.1U18DA052345-01 | DEVI, LAKSHMI A | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $247,028 | ZDA1 |
| 2021 | Glycosylated Endomorphin Analogs for Treatment of Opioid Use Disorder (OUD)1U18DA052539-01 | ZADINA, JAMES E | TULANE UNIVERSITY OF LOUISIANA, LA | $241,450 | ZDA1 |
| 2021 | Regulator of G protein Signaling-12 (RGS12) as a target for SUD therapeutics development1U18DA052497-01 | SETOLA, VINCENT | WEST VIRGINIA UNIVERSITY, WV | $222,568 | ZDA1 |
| 2021 | Novel modulators of ÃÂñ7 nAChRs as treatments for nicotine reward1U18DA052553-01 | BEATON, GRAHAMFORSTER, MICHAEL J.UTESHEV, VICTOR V | EPIGEN BIOSCIENCES, INC., CA | $192,907 | ZDA1 |
| 2020 | Strategy for synthetic cannabinoid abuse and toxicity1U18DA052495-01 | MAITRA, RANGAN | RESEARCH TRIANGLE INSTITUTE, NC | $352,851 | ZDA1 |
| 2020 | Development of GPR3 probes as a novel target for nicotine cessation1U18DA052416-01 | GAY, ELAINE ARRINGTON | RESEARCH TRIANGLE INSTITUTE, NC | $316,773 | ZDA1 |
| 2020 | Targeting organic cation transporter 3 in treatment of substance use disorders1U18DA052527-01 | DAWS, LYNETTE C | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $296,485 | ZDA1 |
| 2020 | Validation of Neuropeptide FF Receptors as Targets for Methamphetamine Use Disorder1U18DA052414-01 | NGUYEN, THUY | RESEARCH TRIANGLE INSTITUTE, NC | $266,775 | ZDA1 |
| 2020 | Targeting Cav1.2 to treat Ketamine-Induced Pathology1U18DA052346-01 | YU, WEIQUN | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $262,500 | ZDA1 |
| 2020 | Dimethyl fumarate attenuation of opioid withdrawal symptom severity1U18DA052344-01 | KAUFMAN, MARC J | MCLEAN HOSPITAL, MA | $245,993 | ZDA1 |
| 2020 | Erythropoietin and Melatonin Combination Therapy for Perinatal Opioid-Induced Brain Injury1U18DA052402-01 | JANTZIE, LAUREN LEIGH COONEY | JOHNS HOPKINS UNIVERSITY, MD | $245,625 | ZDA1 |
| 2020 | Pharmacological Characterization of KCC2 as a Target for Cocaine Use Disorder1U18DA052399-01 | DANI, JOHN A. | UNIVERSITY OF PENNSYLVANIA, PA | $243,188 | ZDA1 |
| 2020 | Synaptic vesicle glycoprotein 2C (SV2C) and psychostimulant actions1U18DA052498-01 | MILLER, GARY W | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $242,269 | ZDA1 |
| 2020 | Stimulation of an ectopic olfactory receptor to reverse ventilatory depression induced by opioids1U18DA052505-01 | CHANG, ANDY J. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $242,250 | ZDA1 |
| 2020 | Validation and pharmacological profiling of a non-psychoactive THC analog, a novel and selective CB2 receptor agonist, in proof of concept studies using rodent models of heroin addiction1U18DA052415-01 | BARRON, ANNELISE EMILYSHAMLOO, MEHRDAD | STANFORD UNIVERSITY, CA | $241,871 | ZDA1 |
| 2020 | Nanodelivery therapeutic systems for substance use disorder1U18DA052394-01 | BAHAL, RAMAN | UNIVERSITY OF CONNECTICUT STORRS, CT | $241,500 | ZDA1 |
| 2020 | A novel functionally selective drug for the treatment of cocaine abuse by antagonism of the beta-arrestin signaling arm of the Ghrelin Receptor1U18DA052417-01 | BARAK, LAWRENCE S. | DUKE UNIVERSITY, NC | $241,500 | ZDA1 |
| 2020 | FGF13: a novel druggable target for treating substance abuse disorders1U18DA052504-01 | LAEZZA, FERNANDA | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $237,000 | ZDA1 |
| 2020 | Validation of GPR52 agonists as a therapeutic approach for stimulant use disorders1U18DA052543-01 | ALLEN, JOHN A | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $237,000 | ZDA1 |
| 2020 | AMPAkines for Novel Opioid Use Disorder Pharmacotherapy1U18DA052545-01 | ANASTASIO, NOELLE CCUNNINGHAM, KATHRYN A.ZHOU, JIA | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $237,000 | ZDA1 |
| 2020 | BRD4 Inhibition for Opioid Pharmacotherapy1U18DA052546-01 | ANASTASIO, NOELLE CCUNNINGHAM, KATHRYN A.ZHOU, JIA | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $237,000 | ZDA1 |
| 2020 | Negative allosteric modulators for the management of Opioid Use Disorder1U18DA052371-01 | ALT, ANDREWTRAYNOR, JOHN R. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $234,000 | ZDA1 |
| 2020 | Pharmacological activators of Nr4a1 for the treatment of cocaine use disorders1U18DA052513-01 | HELLER, ELIZABETH A | UNIVERSITY OF PENNSYLVANIA, PA | $233,112 | ZDA1 |
| 2020 | Targeting astrocyte iNOS to inhibit cocaine-induced neurovascular deficits in PFC1U18DA052366-01 | DU, CONGWUYIN, WEI | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $232,524 | ZDA1 |
| 2020 | Reduction of psychostimulant craving through positive allosteric modulation of mGlu11U18DA052488-01 | WOLF, MARINA ELIZABETH | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $230,471 | ZDA1 |
| 2020 | VALIDATING THE NOCICEPTIN RECEPTOR FOR TREATING CRAVING AND WITHDRAWAL-ASSOCIATED AFFECT IN COCAINE ADDICTION PHARMACOTHERAPY1U18DA052559-01 | ZAVERI, NURULAIN T | ASTRAEA THERAPEUTICS, LLC, CA | $229,620 | ZDA1 |
| 2020 | Validation of ghrelin hydrolysis as an effective approach to treatment of substance use disorders1U18DA052319-01 | ZHENG, FANG | UNIVERSITY OF KENTUCKY, KY | $229,500 | ZDA1 |
| 2020 | BRD4 Inhibitor1U18DA052533-01 | WAHLESTEDT, CLAES ROBERT | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $219,528 | ZDA1 |
| 2020 | Dual Fatty Acid Amide Hydrolase (FAAH) and Monoacyglycerol Lipase (MAGL) Inhibitors as Novel Agents for Treatment of Cannabis Use Disorder (CUD)1U18DA052537-01 | ALAPAFUJA, SHAKIRU OLAJIRE | MAKSCIENTIFIC, LLC, MA | $218,855 | ZDA1 |
| 2020 | Validation of CD74 as a treatment target for methamphetamine use disorder1U18DA052351-01 | HUCKANS, MARILYNLOFTIS, JENNIFER M | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $199,362 | ZDA1 |
| 2020 | New Therapeutics for Treating Cocaine Addiction Targeting D1-D2 Heteromers1U18DA052509-01 | SROMEK, ANNA WACLAWA | MCLEAN HOSPITAL, MA | $119,767 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.